Fulcrum Therapeutics, Inc. - 8-K Filing
Fulcrum Therapeutics discontinued its pociredir program for sickle cell disease following FDA feedback concerning malignancy risks linked to PRC2 inhibitors, including Tazverik (tazemetostat), which was globally withdrawn in March 2026. The company also announced a strategic review of alternatives to maximize stockholder value and has $333.3 million in cash as of March 31, 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $FULC